Application of camrelizumab combined with endostar in advanced non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300079300

Enrollment

Unknown

Registered

2023-12-29

Start date

2021-06-05

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Test group:camrelizumab combined with endostar

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Subjects voluntarily join the study and sign the informed consent; 2. Advanced non-small cell lung cancer confirmed by pathological examination; 3. ECOG score ? 3 or patients who refuse chemotherapy; 4. Age = 18 years old; 5. Have measurable tumor lesions (helical CT scan =10mm, meet RECIST 1.1 standard); 6. Liver, kidney function, blood routine, and heart function are basically normal before medication; 7. Expected survival period = 3 months.

Exclusion criteria

Exclusion criteria: 1. Patients with mutations in driver genes EGFR and ALK/ROS-1 fusion genes; 2. People who are contraindicated in the application of anti-immune checkpoint inhibitors and anti-vascular targeted drugs; 3. Any other conditions that the investigator believes that the patient is not suitable for participating in this study.

Design outcomes

Primary

Measure	Time frame
Objective Response Rate;	—

Secondary

Measure	Time frame
Disease Control Rate;Quality of Life;	—

Countries

China

Contacts

Public ContactSun Liqiu

Mudanjiang Cancer Hospital

sunliqiu0331@163.com+86 135 1454 8838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026